• Journal of Korean society of Dental Hygiene
• /
• v.14 no.3
• /
• pp.431-438
• /
• 2014

Objectives : The purpose of the study is to investigate the recognition between laypersons and dental hygienists on expansion of health insurance of scaling. Methods : A self-reported questionnaires was filled out by 100 laypersons and 100 dental hygienists from October 7, 2013. Data were analyzed by SPSS version 21.0 program. Results : All the dental hygienists recognized the introduction of the health insurance of scaling and 71.0% of the laypersons agreed. The introduction of health insurance of scaling was responsible for the interest toward scaling in 80 dental hygienists(80.0%) and 66 laypersons(66.0%). 94% of dental hygienists answered that health insurance of scaling would prevent periodontal diseases. The expansion of health insurance of scaling revealed many periodontal diseases and 52% of laypersons answered that prevention of periodontal diseases would deprive the dental hygienists of their jobs. Conclusions : The expansion of health insurance of scaling can prevent the periodontal diseases and enhance the oral health services. So the government must try to expand the health insurance of scaling.

• The Journal of the Korean dental association
• /
• v.51 no.8
• /
• pp.451-458
• /
• 2013

Human immunodeficiency virus is a retrovirus that causes acquired immunodeficiency syndrome. Acquired immunodeficiency syndrome is defined in terms of "either the occurrence of specific diseases in association with a HIV infection or a CD4 cell count below 200cells/ul" by centers for disease control and prevention(CDC). When performing the surgery of human immunodeficiency virus infected patients, several factors should be considered. First, standard precautions should be performed to prevent infection. It is safe to treat human immunodeficiency virus infected patients if we follow the standard precautions. Second, when making a surgical plan, surgeons have to take account of delayed bone healing and postsurgical infection. This case report presents a case of orthognathic surgery of human immunodeficiency virus infected patient.

• Food Science and Biotechnology
• /
• v.14 no.2
• /
• pp.286-289
• /
• 2005

Active antibacterial compound against periodontitis-causing bacterium Porphyromonas gingivalis was isolated from Kaempferia pandurata and identified as panduratin A. Minimum inhibitory concentration (MIC) value of panduratin A was $4\;{\mu}g/mL$, much lower than those of other natural antibacterial agents. Panduratin A also showed antibacterial activity against Prevotella intermedia ($2\;{\mu}g/mL$), P. loescheii ($4\;{\mu}g/mL$), and cariogenic Streptococcus mutans ($4\;{\mu}g/mL$). Damage on cell wall and perturbation of cytoplasmic membrane of panduratin A-treated P. gingivalis were visualized through transmission electron microscopy. These results suggest panduratin A, exhibiting strong and preferential antiperiodontal and anticariogenic activities, may be utilized in functional foods for prevention of oral diseases.

• Animal cells and systems
• /
• v.11 no.1
• /
• pp.33-38
• /
• 2007

Liposome-entrapped atypical Aeromonas hydrophila antigen was prepared to investigate the potential protective efficacy for A. hydrophila infection. Carp (Cyprinus carpio) were immunized orally with liposome-entrapped A. hydrophila antigen. After immunization, significantly more antigen-specific antibodies were detected in serum, intestinal mucus and bile than non-immunized control group. The immunized carp were then challenged by immersion with $1{\times}10^{6}$ cfu/ml of A. hyrdophila for 60 min. Of the eight non-immunized carp, three carp died (62.5% survival), whereas five out of six (83.5%) of the immunized survived. Furthermore, development of skin ulcers was significantly inhibited in carp immunized with liposomes containing A. hydrophila antigen. These results suggest that liposomes containing A. hydrophila antigen have a potential for induction of protective immune responses against atypical A. hydrophila infection and also suggest the possibility of developing a vaccine that may ultimately be used for prevention of fish diseases.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• v.47 no.6
• /
• pp.445-453
• /
• 2021

Objectives: Periodontitis is the most common chronic disease that causes tooth loss and is related to systemic diseases such as cardiovascular disease and diabetes. An objective indicator of the current activity of periodontitis is necessary. Soluble forms of the receptor for advanced glycation end products (sRAGE) are markers that reflect the status of inflammatory diseases. In this study, the relationship between sRAGE and periodontitis was analyzed to determine whether it can be used to diagnose the current state of periodontitis. Patients and Methods: Eighty-four patients without any systemic diseases were diagnosed with periodontitis using three classifications of periodontitis. Demographics and oral examination data such as plaque index (PI), bleeding on probing (BOP) index, and probing pocket depth (PPD) were analyzed according to each classification. In addition, correlation and partial correlation between sRAGE and the values indicating periodontitis were analyzed. Results: In each classification, the level of sRAGE tended to decrease if periodontitis was present or severe, but this change was not statistically significant. sRAGE and periodontitis-related variables exhibited a weak correlation, among which the BOP index showed a relatively strong negative correlation (ρ=-0.20). Based on this, on analyzing the correlation between the BOP index and sRAGE in the group with more severe periodontitis (PPD≥5 mm group, severe group of AAP/CDC [American Academy of Periodontology/Centers for Disease Control and Prevention], periodontitis group of López), the correlation further increased (ρ=-0.23, -0.40, -0.50). Partial correlation analysis of the sRAGE and BOP index showed a stronger negative correlation (ρ=-0.36, -0.55, -0.45). Conclusion: sRAGE demonstrated a tendency to decrease upon increased severity of periodontitis according to the classifications used. Above all, the correlation with the BOP index, which reflects the current state of periodontitis, was higher in the group with severe periodontitis. This indicates that the current status of periodontitis can be diagnosed through sRAGE.

• Journal of Oral Medicine and Pain
• /
• v.34 no.2
• /
• pp.169-177
• /
• 2009

Recently it is very interesting that the plant extracts use to prevent or treat the oral diseases. The present study was performed to observe the antibacterial effect on S. gordonii Challis, S. gordoii G9B, S. mutans GS5, S. sobriuns 6715, E. faecalis ATCC 4083, A. actinomycetem Y4, P. gingivalis A7A1-28, P. gingivalis W83, Pr. intermedia ATCC 25611, F. nucleatum KTCT 2488, C. albicans ATCC 18804 of Artemisa capillaris THUNB employing the viable cell counts. The results were as follows: 1. Minimum inhibitory concentration(MIC) and Minimum bactericidal concentration(MBC) of extracts of Artemisa capillaris THUNB for P. gingivalis A7A1-28, P. gingivalis W83, and Pr. intermedia ATCC 25611, which are the pathologic bacteria of periodontal diseases, was observed under 2%. 2. MIC of extracts of Artemisa capillaris THUNB for P. gingivalis A7A1-28 was determined to be 1.2% and MBC was determined to be 2.0% respectively. 3. MIC of extracts of Artemisa capillaris THUNB for P. gingivalis W83 was determined to be 1.4% and MBC was determined to be 2.0% respectively. 4. MIC of extracts of Artemisa capillaris THUNB for Pr. intermedia ATCC 25611 was determined to be 1.2% and MBC was determined to be 2.0% respectively. The overall results indicate that Artemisa capillaris THUNB used for this study has a strong antibacterial activity against P. gingivalis A7A1-28, P. gingivalis W83, and Pr. intermedia ATCC 25611, which are the periodontopathic bacteria. Therefore, the extracts of Artemisa capillaris THUNB can be used as a candidate for prevention and therapeutic agent against periodontal diseases.

• The Journal of Internal Korean Medicine
• /
• v.30 no.2
• /
• pp.355-364
• /
• 2009

Objectives : Benign prostatic hyperplasia (BPH) is one of the most common diseases among elderly men. Though medicines such as 5${\alpha}$-reductase inhibitor (finasteride) have recently been developed for treating BPH, their adverse effects and low efficacy should not be overlooked. Curcuma longa has a long history of use in traditional medicines of Asian countries. Many reports conclude the component curcumin in Curcuma lonfa, has the potential to treat various diseases including prostate cancer. In this study, we investigated the therapeutic effects and action mechanism of Curcuma longa with a BPH rat model. Methods : Sprague-Dawley rats were used with subcutaneous injection of testosterone after castration, which were histologically similar to human BPH. A total of 30 rats were equally divided into five groups: Group 1 served as control (sham-operated group): Group 2 was the model group: Group 3 and Group 4 animals were administered Curcuma longa at dose levels of 0.5g/kg and 1.0g/kg: Group 5 served as a positive control group and was treated with finasteride at a dose of 1 mg/kg. The drugs were administered orally once a day for 30 days consecutively. After 31 days, the prostates were removed, and analyzed for their prostatic weight and histological examination. Results : The oral Curcuma longa ingestion group showed statistically significant decreases in their prostatic weights compared with the BPH-induced group and the oral finasteride ingestion group (p<0.05). Curcuma longa is also very safe in liver and kidney up to a dose of lg/kg. Injected testosterone histologically led to prostatic hyperplasia in rats, but oral Curcuma longa ingestion decreased this change. Conclusions : These results suggest that Curcuma longa has a definite inhibitory effect on BPH and might be an alternative medicine for treatment and prevention of human BPH.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.3
• /
• pp.837-846
• /
• 2012

Breast cancer (BCa) is the leading type of cancer in Mexican women. Genetic factors, such as single nucleotide polymorphisms (SNP) of P450 system, have been reported in BCa. In this report, and for the first time in the literature, we analyzed the rs3735684 (7021 G>A), rs11553651 (15016 G>T) and rs56195291 (60020 C>G) polymorphisms in the CYP2W1, 4F11 and 8A1 genes in patients with BCa and in healthy Mexican women to identify a potential association between these polymorphisms and BCa risk. Patients and controls were used for polymorphism analysis using an allelic discrimination assay with TaqMan probes and confirmed by DNA sequencing. Links with clinic-pathological characteristics were also analyzed. Statistical analysis was performed using the standard ${\chi}^2$ or Fisher exact test statistic. No significant differences were observed in the distributions of CYP2W1 (OR 8.6, 95%CI 0.43-172.5 P>0.05; OR 2.0, 95%CI 0.76-5.4, P>0.05) and CYP4F11 (OR 0.3, 95%CI 0.01-8.4 P>0.05) genotypes between the patients and controls. Only the CYP8A1 CC genotype was detected in patients with BCa and the controls. All polymorphism frequencies were in Hardy-Weinberg Equilibrium (HWE) in the controls (P>0.05). We found a significant association between BCa risk and smoking, use of oral contraceptives or hormonal replacement therapy (HRT), obesity, hyperglycemia, chronic diseases, family history of cancer and menopausal status in the population studied (P<0.05). Tobacco, oral contraceptive or HRT, chronic diseases and obesity or overweight were strongly associated with almost eight, thirty-five, nine and five-fold increased risk for BCa. Tobaco, obesity and hyperglycemia significantly increased the risk of BCa in the patients carrying variant genotypes of CYP2W1 (P<0.05). These results indicate that the CYP2W1 rs3735684, CYP4F11 rs11553651 and CYP8A1 rs56195291 SNPs are not a key risk factor for BCa in Mexican women. This study did not detect an association between the CYP2W1, 4F11 and 8A1 genes polymorphisms and BCa risk in a Mexican population. However, some clinico-pathological risk factors interact with CYP2W1 genotypes and modifies susceptibility to BCa.

• Archives of Obesity and Metabolism
• /
• v.1 no.1
• /
• pp.14-25
• /
• 2022

In 1971, Dr. Akira Endo succeeded in isolating a cholesterol synthesis inhibitor, compactin. Later, compactin was renamed mevastatin, meaning that it stops the synthesis of mevalonate, which is considered the first statin. However, mevastatin is not commercially released, whereas lovastatin, developed by Alfred Albert of Merk in 1979, was the first commercially developed statin. After the 4S study, the first largescale clinical trial with statins conducted in Scandinavia showed a dramatic secondary preventive effect against cardiovascular disease, and the effectiveness of statins in patients with dyslipidemia was repeatedly demonstrated. Subsequently, many oral drugs that affect blood lipid concentration; statins and ezetimibe aimed at reducing low-density lipoprotein (LDL)) cholesterol; fibrates and omega 3 formulations aimed at reducing triglycerides were widely developed and used in Korea. In this article, we review the results of clinical studies on representative cardiovascular diseases for four types of oral drugs for dyslipidemia, which are currently the most commonly used in Korea.

• Proceedings of the Korean Society of Food Science and Nutrition Conference
• /
• 2001.12a
• /
• pp.69-73
• /
• 2001

Two opioid peptides, YPLDL and YPLDLF, were isolated from enzymatic digests of spinach ribulose-1, 5-bisphosphate carboxylase/oxygenase (RuBisCO) and named rubiscolin-5 and -6, respectively. These peptides were selective for delta-receptor and the latter was about 3 times more potent than the former. After oral administration in mice at the dose of 100 mg/kg, rubiscolin-6 showed analgesic activity in tail pinch test. It also stimutated learning performance at the same dose in passive avoidance experiment using step-through apparatus. An immunostimulating peptide, MITLAIPVNKPGR, was isolated from a trypsin digest of soybean protein and named soymetide. Immunostimulating activy of soymetide was mediated by fMLP receptor. Interestingly, after oral administration in rats at a dose of 300 mg/kg (po.), soymetide-4 (MITL) protected alopecia (hair-loss) induced by etoposide, a cancer chemotherapy agent. Stimulation of IL-1 release by the peptide was involved in the mechanism. Ovokinin(2-7), RADHPF, is a vasorelaxing peptide released from ovalbumin by the action of chymotrypsin. It lowered blood pressure of spontaneously hypersensive rats (SHR) after oral administration at a dose of 10 mg/kg. RPLKPW, which was designed by replacing 4 amino acid residues in ovokinin(2-7), exhibited hypotensive activity at a dose of 0.1 mg/kg (po.). This peptides was introduced into 3 homologous sites in soybean beta-conglycinin alpha' subunit by site-directed mutagenesis of the cDNA and expressed in E. coli. The minimum effective dose for hypotensive activity of the genetically modified beta-conglycinin alpha' subunit was 10 mg/kg (po.), which is about 1/200 that of ovalbumin.